YLL059C Antibody

What is YLL059C and why are antibodies against it important for research?

YLL059C is a systematic gene identifier in Saccharomyces cerevisiae (baker's yeast) that encodes a protein involved in cellular processes. Antibodies against this protein are crucial research tools for studying yeast cellular mechanisms, protein-protein interactions, and cellular localization patterns. These antibodies enable researchers to detect, track, and quantify the YLL059C protein product in various experimental conditions, providing insights into gene expression and protein function that contribute to our understanding of fundamental biological processes in eukaryotic cells . The study of yeast proteins through antibody-based techniques is particularly valuable as many yeast genes have homologs in humans, making findings potentially translatable to human biology and disease research.

What types of antibodies are available for yeast protein research?

Two main categories of antibodies are commonly used in yeast protein research:

• Polyclonal antibodies: Generated by immunizing animals with purified yeast proteins or synthetic peptides derived from the protein sequence. These recognize multiple epitopes on the target protein.

• Monoclonal antibodies: Produced using hybridoma technology or recombinant methods. These bind to specific epitopes with high specificity.

How can I evaluate the specificity of a YLL059C antibody?

Evaluating antibody specificity is critical for reliable research results. For YLL059C antibody validation, implement these methodological approaches:

• Western blot analysis with controls: Run protein extracts from wild-type yeast alongside YLL059C knockout strains. A specific antibody will show bands of the expected molecular weight in wild-type samples but not in knockout samples.

• Immunoprecipitation followed by mass spectrometry: Verify that the antibody pulls down the intended YLL059C protein target from yeast lysates.

• Immunofluorescence microscopy: Compare staining patterns in wild-type versus YLL059C knockout or knockdown strains.

• Cross-reactivity testing: Test the antibody against closely related yeast proteins to ensure specificity.

• Epitope mapping: Determine the exact binding region to understand potential cross-reactivity with similar protein domains .

Comprehensive validation using multiple techniques provides the highest confidence in antibody specificity.

How should I design experiments using YLL059C antibodies for cell cycle research?

When designing experiments to study YLL059C in the context of cell cycle regulation, consider these methodological principles:

• Synchronization strategy: Before antibody application, implement reliable cell synchronization methods. Choose between α-factor arrest, centrifugal elutriation, or temperature-sensitive cdc mutants based on your specific research questions.

• Time-course sampling: Collect samples at defined intervals throughout the cell cycle (typically every 10-15 minutes for 2-3 hours) to capture dynamic changes in YLL059C protein levels or modifications.

• Multimodal approach: Combine antibody-based detection with gene expression analysis. As demonstrated in recent research: "Our idea of introducing the available information about transcription factors to optimize the gene classification could be implemented for other distance-based clustering algorithms" . This integration provides more comprehensive insights into cell cycle-dependent regulation.

• Essential controls: Include samples from cells arrested at different cell cycle phases (G1, S, G2/M) as reference points, alongside non-specific antibody controls and YLL059C mutant strains when available.

• Quantification method: Implement rigorous quantification protocols, ideally using fluorescence-based techniques with appropriate normalization to housekeeping proteins.

What are the optimal antibody concentrations for different applications?

Determining optimal antibody concentrations is critical for obtaining reliable results while minimizing background and controlling costs. Based on systematic titration studies of antibodies:

• Western blotting: Begin titration at 0.625-2.5 μg/mL, as "most antibodies appear to reach their saturation plateau at concentrations between 0.62 and 2.5 μg/mL" . For YLL059C detection, a starting concentration of 1 μg/mL is recommended, followed by optimization.

• Immunofluorescence: Start with 1-5 μg/mL for fixed yeast cells, with overnight incubation at 4°C. Titrate in twofold dilutions if background is high.

• Flow cytometry: Initial concentration of 0.625-2.5 μg/mL is suitable, as "antibodies used at concentrations below 0.625 μg/mL show linear or close to linear response" .

• Immunoprecipitation: Higher concentrations (5-10 μg per reaction) are typically required, but excess antibody can increase non-specific binding.

• Chromatin immunoprecipitation: Usually requires 2-5 μg of antibody per 10^6 cells.

Research shows that "oligo-conjugated antibodies show high background and limited response to titration when used above 2.5 μg/mL" , so concentration optimization is essential for all applications. For multiplex experiments, adjust individual antibody concentrations to balance signal intensity across targets.

How can I optimize YLL059C antibody staining for single-cell analysis?

For single-cell analysis applications using YLL059C antibodies, consider these optimization strategies:

• Volume optimization: Research indicates that "reducing staining volume has a minor effect on signal and only impacts signal from antibodies used at low concentrations targeting highly expressed epitopes" . For yeast samples, start with 25-50 μL staining volumes for 0.2-1×10^6 cells.

• Concentration titration: Perform fourfold serial dilutions starting from 2.5 μg/mL. As noted in current research: "We find that oligo-conjugated antibodies show high background and limited response to titration when used above 2.5 μg/mL" .

• Cell density adjustment: Control cell numbers during staining as "this effect is counteracted by reducing the number of cells present during staining" . Optimal number for yeast cells is typically 0.5-1×10^6 cells per staining reaction.

• Buffer optimization: Test different blocking agents (BSA, normal serum, non-fat milk) at 1-5% concentrations to minimize non-specific binding.

• Permeabilization protocol: For intracellular yeast proteins, optimize cell wall digestion (with zymolyase or lyticase) and membrane permeabilization times carefully.

This systematic approach has been shown to "increase signal, lower background, and reduce both sequencing and antibody costs" in single-cell analysis applications.

How can I use YLL059C antibodies to study protein-protein interactions in stress response pathways?

Investigating protein-protein interactions involving YLL059C during stress response requires sophisticated methodological approaches:

• Co-immunoprecipitation (Co-IP) with tandem mass spectrometry: Use the YLL059C antibody to pull down protein complexes before and after stress induction (e.g., nutrient limitation, oxidative stress, heat shock). Follow with mass spectrometry to identify interacting partners. This approach can reveal "novel genes not yet reported as involved in programmed cell death, that are co-expressed with genes known (from literature) to be associated to programmed cell death" .

• Proximity-dependent biotinylation (BioID or TurboID): Fuse a biotin ligase to YLL059C and use your validated antibody to confirm expression and localization of the fusion protein while identifying proximal proteins.

• Bimolecular fluorescence complementation (BiFC): Tag potential interacting partners with split fluorescent protein fragments and use the YLL059C antibody to verify expression levels of the fusion proteins.

• Förster resonance energy transfer (FRET): Measure protein interactions in living cells and confirm expression using your YLL059C antibody in parallel samples.

• Chromatin immunoprecipitation (ChIP): If YLL059C has nuclear functions, identify DNA binding sites during normal and stress conditions.

Recent research indicates that "implementing biosensors to monitor cell response" using these antibody-based approaches can provide critical insights into stress response mechanisms. When analyzing results, compare the YLL059C interaction network under stress with normal conditions to identify stress-specific interactions.

What are the best approaches for quantifying YLL059C protein in different yeast compartments?

For precise quantification of YLL059C protein across different subcellular compartments, implement these methodological approaches:

• Subcellular fractionation with immunoblotting: Systematically separate cellular compartments (cytosol, nucleus, mitochondria, ER, vacuole) using differential centrifugation or density gradient techniques. Quantify YLL059C in each fraction using validated antibodies with appropriate loading controls for each compartment.

• Quantitative immunofluorescence microscopy: Perform co-localization with established compartment markers (e.g., DAPI for nucleus, MitoTracker for mitochondria) and implement rigorous image analysis protocols.

• Proximity ligation assay (PLA): Combine the YLL059C antibody with antibodies against compartment-specific proteins to quantify proximity events in fixed cells.

• Electron microscopy with immunogold labeling: For ultrahigh resolution analysis of YLL059C distribution, use gold-conjugated secondary antibodies and quantify gold particle density across compartments.

• Flow cytometry of permeabilized organelles: For high-throughput analysis, isolate specific organelles, permeabilize, and stain with fluorescently labeled YLL059C antibodies.

The quantification approach should be calibrated using appropriate standards, as recent research emphasizes that "an optimal panel would ideally use similar number of UMIs per positive cell for each antibody" when conducting multiplexed analyses.

How should I analyze contradictory results between different antibody-based techniques?

When faced with contradictory results between different antibody-based detection methods for YLL059C protein, implement this systematic troubleshooting approach:

• Epitope accessibility assessment: Different techniques expose different protein regions. As research indicates, selecting antibodies that bind to specific domains is critical: "Selection of a non-inhibitory antibody that binds to an idiotope outside the antigen binding site of the drug results in an antibody that can be used to detect both free and bound drug in the sample" . Apply this concept to your YLL059C antibody by determining if your epitope might be masked in certain techniques.

• Cross-validation strategy: Implement multiple antibody-based methods targeting different epitopes of the YLL059C protein. Consider developing "Type 1" (binding to functional domains) and "Type 2" (binding to accessible surface regions) antibodies as described in current research .

• Technical validation: For each technique showing contradictory results:

  • Verify antibody specificity using knockout controls

  • Check for interfering post-translational modifications

  • Assess buffer compatibility with epitope recognition

  • Confirm protein denaturation status matches antibody requirements

• Biological validation: Use orthogonal methods that don't rely on antibodies, such as:

  • Mass spectrometry for protein identification and quantification

  • Functional assays specific to YLL059C biological activity

  • Genetic manipulations (overexpression, depletion) with phenotypic readouts

• Statistical analysis: Apply appropriate statistical methods to determine significance of differences, accounting for technical and biological variability.

What are the best practices for normalizing YLL059C antibody signals in quantitative applications?

Proper normalization is essential for reliable quantitative analysis of YLL059C protein levels. Implement these methodological best practices:

• Loading control selection: Choose appropriate loading controls based on your experimental context:

  • For steady-state measurements: Constitutively expressed proteins (actin, GAPDH)

  • For dynamic cellular processes: Multiple loading controls representing different expression patterns

  • For subcellular fractions: Compartment-specific markers as shown in question 3.2

• Technical normalization approaches:

  • Include calibration standards on each gel/blot

  • Use total protein normalization methods (Ponceau S, SYPRO Ruby)

  • Implement housekeeping protein panels rather than single controls

• Signal quantification methodology: Research demonstrates that "an optimal panel would ideally use similar number of UMIs per positive cell for each antibody and exhibit approximately the same positive signal" . Apply this principle by:

  • Using digital image analysis with background subtraction

  • Ensuring signals fall within the linear detection range

  • Employing ratio-metric analysis when appropriate

• Statistical validation: Implement appropriate statistical methods:

  • Calculate coefficient of variation across technical replicates (<15% is typical benchmark)

  • Apply proper statistical tests for group comparisons

  • Consider power analysis to determine required sample sizes

• Cross-platform validation: Verify findings using multiple antibody-based techniques (e.g., Western blot, ELISA, flow cytometry) with technique-specific normalization.

How can I integrate YLL059C antibody data with gene expression analyses?

Integrating protein-level data from YLL059C antibody experiments with transcriptomic analyses requires sophisticated methodological approaches:

• Temporal correlation analysis: Design experiments to collect matched samples for both protein (antibody-based) and mRNA (RNA-seq) measurements across relevant timepoints. Research indicates that "analysis of RNA-seq data related to programmed cell death both for Saccharomyces cerevisiae and Homo sapiens" can be enhanced by integrating protein-level data.

• Multi-omics data integration frameworks:

  • Implement canonical correlation analysis (CCA) to identify relationships between protein and transcript datasets

  • Apply weighted gene co-expression network analysis (WGCNA) to identify modules of co-regulated genes and proteins

  • Use pathway enrichment analysis to contextualize integrated findings

• Protein-mRNA correlation modeling: Apply machine learning approaches to model:

  • Time lags between transcription and translation

  • Effects of post-transcriptional regulation

  • Protein stability factors influencing steady-state levels

• Validation experiments: Design targeted experiments to test hypotheses generated from integrated analysis:

  • Mutate regulatory regions and measure effects on both mRNA and protein

  • Modulate post-transcriptional regulators and assess impact

  • Inhibit protein degradation pathways and measure resulting changes

• Visualization and interpretation: Develop comprehensive visualization approaches that present protein and transcript data in an integrated format. Recent research has shown benefits of "clustering algorithm for gene expression data" that can be applied to integrated protein-mRNA datasets.

This integrated approach provides deeper insights than either dataset alone, as research shows that "gene expression data from nutrigenomics experiments" can be effectively combined with protein-level data to identify novel regulatory mechanisms.

What are common pitfalls in YLL059C antibody experiments and how can they be addressed?

When working with YLL059C antibodies, researchers frequently encounter these challenges, which can be addressed with specific methodological solutions:

• High background signal:

  • Problem: Non-specific binding leading to false-positive signals

  • Solution: "Reducing staining volume has a minor effect on signal" , but optimizing antibody concentration is critical. Research shows that "oligo-conjugated antibodies show high background and limited response to titration when used above 2.5 μg/mL" . Implement stringent blocking with 5% BSA or normal serum matched to secondary antibody species, and include non-specific antibody controls.

• Inconsistent results between experiments:

  • Problem: Variability in antibody performance across batches

  • Solution: Create a master validation protocol for each new antibody lot. Document key performance metrics and maintain reference samples for comparison. Implement positive and negative controls in every experiment.

• Poor signal-to-noise ratio:

  • Problem: Weak specific signal relative to background

  • Solution: Research indicates that "adjusting concentrations increases signal, lowers background, and reduces both sequencing and antibody costs" . Optimize primary antibody concentration, incubation time/temperature, and detection system sensitivity.

• Epitope masking:

  • Problem: Inaccessible epitopes due to protein folding or interactions

  • Solution: Test multiple fixation and sample preparation methods. Consider epitope retrieval techniques (heat, pressure, or pH-based) adapted for yeast cells.

• Cross-reactivity with related proteins:

  • Problem: Antibody recognizing proteins other than YLL059C

  • Solution: Validate with YLL059C deletion strains. Perform Western blots with recombinant proteins of related family members to assess cross-reactivity.

How can I determine if my YLL059C antibody is detecting the native protein versus modified forms?

Distinguishing between native and modified forms of YLL059C protein requires these methodological approaches:

• Modification-specific detection strategy:

  • Use phosphatase or deglycosylation enzymes to remove modifications

  • Compare migration patterns before and after treatment by Western blot

  • Implement 2D gel electrophoresis to separate modified forms by charge and size

• Mass spectrometry validation:

  • Perform immunoprecipitation with your YLL059C antibody

  • Analyze precipitated proteins using LC-MS/MS

  • Identify post-translational modifications and their stoichiometry

• Epitope mapping:

  • Determine whether the antibody epitope contains potential modification sites

  • Generate synthetic peptides with and without modifications

  • Test antibody binding to modified and unmodified peptides

• Complementary antibody approach:

  • Obtain or develop modification-specific antibodies (e.g., phospho-specific)

  • Compare signals between pan-YLL059C and modification-specific antibodies

  • Use ratios to determine modification states under different conditions

• Functional correlation:

  • Correlate detection of particular forms with known cellular functions

  • Use mutants that prevent specific modifications

  • Apply inhibitors of modification enzymes and assess antibody detection patterns

This approach aligns with current research emphasizing that "implementing biosensors to monitor cell response" requires precise characterization of protein modification states.